Counterfeit semaglutide and tirzepatide vials seized in West Tennessee raid

Officers in West Tennessee seized 300-plus fake vials of semaglutide and tirzepatide while searching a home in Medina, Tennessee, and charged a 41-year-old woman with selling counterfeit weight loss drugs, the West Tennessee Drug Task Force said ^[1].

The case began about two months before the Dec. 17, 2024, announcement, when a tipster told law enforcement that someone in the area was offering cheap versions of Ozempic and other weight loss medicines ^[1]. What raised suspicion was the pricing. According to the task force, a 10-milligram vial of semaglutide — the molecule sold as Ozempic, Wegovy and Rybelsus — was priced at about $100, and a 15-milligram vial at $140. Novo Nordisk's branded semaglutide runs about $1,000 for a month's supply ^[1].

During the raid, which happened the week before the announcement, officials took the counterfeit semaglutide and tirzepatide vials, along with other weight loss drugs, syringes, alcohol preps, mailers and additional supplies ^[1]. Tirzepatide is the molecule in Mounjaro and Zepbound. "We stumbled into one room that was set up, sort of like a lab," Johnie Carter, director of the West Tennessee Drug Task Force, said. "We even found three packages that were already packaged up and ready to go." He described it as "very shocking" ^[1].

Officials said the woman, Emily Arnold, allegedly also supplied two med spa clinics in the state ^[1]. Some people who took the counterfeit drugs reported rashes and other pain from the injections ^[1]. She was charged with four felonies and a misdemeanor, including impersonating a licensed professional ^[1]. Her attorney said she will plead not guilty ^[1]. No court date has been reported.

The seized items are not the same as compounded GLP-1 medications, which are legal copies prepared by licensed pharmacists and usually prescribed by doctors, a practice the Food and Drug Administration monitors ^[1]. The FDA is letting pharmacies dispense compounded semaglutide and tirzepatide until brand-name shortages are fully resolved. In October, after a compounding trade group sued the agency, the FDA said pharmacies could keep making their own versions ^[1].

Why it matters for patients

The price difference is central. The task force said the counterfeit vials were selling for roughly $100 to $140, against about $1,000 a month for branded semaglutide from Novo Nordisk ^[1]. That gap was what made the tipster suspicious in the first place ^[1].

What was inside the seized vials has not been disclosed, nor has how they were labeled or whether any were tested ^[1]. Officials did say the products were allegedly routed to two med spa clinics as well as sold directly, and that some users reported rashes and injection pain ^[1].

The counterfeit-versus-compounded distinction is the practical one. Compounded products come from licensed pharmacists working under FDA oversight; counterfeit vials do not ^[1]. People sorting out where a GLP-1 product comes from are choosing between two categories with very different supervision ^[1].

The regulatory backdrop is also shifting. The FDA's allowance for compounded semaglutide and tirzepatide depends on when brand-name shortages are declared resolved, and that policy has already been challenged in court ^[1].

What happens next

Arnold's prosecution is pending, with no hearing or trial date reported ^[1]. Her attorney has said she will plead not guilty ^[1]. On the policy side, the FDA has not declared the brand-name shortages fully resolved, so compounded versions remain available under the current allowance ^[1].